TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04880512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX 1901 tablets
Description: SYHX 1901, oral tablets, in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX 1901 tablets
Description: SYHX 1901, oral tablets, in fasted state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral tablets, in fasted state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral tablets, in fasted state
Study: NCT04782089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors
Description: Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
Study: NCT05251909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
Study: NCT05520931

Intervention type: OTHER
Intervention: Questionnaire and register-based data assessment
Description: Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.

Intervention type: OTHER
Intervention: Questionnaire and register-based data assessment
Description: Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
Study: NCT06346990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holy Quran Recital
Description: Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
Study: NCT05792631

Intervention type: DEVICE
Group type: OTHER
Intervention: Near infra red imaging
Description: The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization.
Study: NCT06315179

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy w/ biopsy
Description: Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy w/ biopsy
Description: Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.
Study: NCT06608043

Intervention type: BEHAVIORAL
Intervention: Reborn lifestyle adjustment program
Description: The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules.

Intervention type: PROCEDURE
Intervention: Conventional Physiotherapy and Occupational Therapy
Description: Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
Study: NCT06689956

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT06037941

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: E-Nose testing
Description: At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Research blood
Description: Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
Study: NCT06723691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: HRS9531
Study: NCT06706076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH-30643
Description: BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH-30643
Description: BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
Study: NCT06761989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine injection
Description: A single dose of intrathecal morphine is administered prior to induction of general anesthesia. The patient is placed in the lateral decubitus position on the bed and a 25 guage quincke spinal needle is inserted intrathecally at the L4/5 median or paramedian approach to administer 0.2 mg of morphine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound infiltration
Description: Prior to closure of the abdominal wall, a catheter is placed in the preperitoneal space lateral to the surgical incision through the tunneler. The catheter is connected to a prepared infusion pump (275 ml of 0.5% ropivacaine, 4 ml/hr/catheter), and the remaining catheter protruding from the abdomen is secured with a catheterization dressing. The preperitoneal catheter is removed in the afternoon of postoperative day 3.
Study: NCT06761690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid simulated wound training
Description: hybrid simulated wound training
Study: NCT06762262

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Moderate-Intensity continuous training
Description: refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity continuous training
Description: refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency
Study: NCT06237452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VE303
Description: VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.
Study: NCT06760533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy Treatment Session
Description: The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy Treatment Session
Description: The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin 100 mg
Description: Niacin 100 mg (placebo) administered during the psychotherapy treatment session.
Study: NCT06761586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR104
Description: Once or twice a day
Study: NCT06762249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT + Brunnstrom therapy + routine physical therapy
Description: this therapy will be given for 5 days per week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIMT + routine physical therapy
Description: this therapy will be given for 5 days per week for 4 weeks
Study: NCT06761339

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Azka Nasal and Throat for Children
Description: Azka Nasal and Throat for Children is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in pediatric patients. The intervention involves administering 7.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days. The supplement is intended to alleviate symptoms of nasal and throat irritation, reduce phlegm, and improve overall respiratory comfort. Azka Nasal and Throat for Children has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in pediatric respiratory care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prospan cough Syrup
Description: The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
Study: NCT06761846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Chemotherapy
Description: chemotherapy includes SOX and XELOX
Study: NCT06760507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Family History Screening Program
Description: The intervention includes four key steps designed to enhance the family health screening process. Before the visit, clinics will engage in community outreach using tools such as social media, events, and promotional materials to raise awareness and drive appointment scheduling through the updated GA CORE website 2.0. During the visit, the intervention streamlines the screening process by embedding reminders into workflows and simplifying results communication and documentation. Patients receive theory-based communication materials about their results. After the visit, follow-ups are automated using the updated website 2.0, consolidating data tracking and incorporating risk-stratified communication strategies to encourage appropriate cancer screening behaviors.
Study: NCT05899699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAP-FLU ME
Description: Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene .1% gel
Description: Adapalene .1% gel
Study: NCT06028178

Intervention type: DIAGNOSTIC_TEST
Intervention: Droplet digital PCR
Description: Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
Study: NCT05704140

Intervention type: OTHER
Intervention: Catheter based Dialysis
Description: We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
Study: NCT04771936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Exercises
Description: All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Exercises
Description: All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
Study: NCT04966806

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LASIK refractive surgery
Description: laser vision correction for myopic eyes
Study: NCT05312359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation-true stimulus
Description: The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation-true stimulus
Description: The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial alternating current stimulation-sham stimulus
Description: The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial alternating current stimulation-sham stimulus
Description: The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
Study: NCT06022497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal Model Based Emotion Regulation Interventions
Description: The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
Study: NCT05272306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Number of attempts for successful transesophageal echocardiography
Description: Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Number of attempts for successful transesophageal echocardiography
Description: Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: A questionnaire for cardiologist satisfaction
Description: A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: A questionnaire for cardiologist satisfaction
Description: A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: A questionnaire for patient satisfaction
Description: A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: A questionnaire for patient satisfaction
Description: A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
Study: NCT05791695

Intervention type: OTHER
Intervention: Non Applicable
Description: No study-specific interventions for this observational study.
Study: NCT06439888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
Study: NCT04432155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: 30% xenon, 30% oxygen, and 40% nitrogen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30% oxygen, and 70% nitrogen